GSK, 자궁내막암 1차 치료제로 Jemperli의 FDA 승인 획득

Company

GSK

Category

인허가

Drug (API)

Jemperli

Indication

Primary advanced or recurrent endometrial cancer

Official Announcement

https://www.gsk.com/en-gb/media/press-releases/us-fda-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/

BioSpace

https://www.biospace.com/fda/gsk-wins-broad-label-expansion-for-jemperli-in-first-line-endometrial-cancer

Firstword

https://firstwordpharma.com/story/5881521

Fierce Group

https://www.fiercepharma.com/pharma/gsk-blows-jemperli-marching-brass-against-keytruda-expanded-nod-endometrial-cancer

Release Date

2024/08/05

TA

Oncology

Type

Approval

Approval DB

Class

Clinical DB

Licensing DB

Licensing DB (1) (Article DB)에 관계됨

Partnership DB

Target

Upload Date

3 more properties

BioSpace

Firstword

Fierce Group